Skip to main content
Beta Drugs Limited logo

Beta Drugs Limited — Investor Relations & Filings

Ticker · BETA ISIN · INE351Y01019 LEI · 984500A89888DB9E6T57 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 431 across all filing types
Latest filing 2024-09-30 Regulatory Filings
Country IN India
Listing National Stock Exchange of India BETA

About Beta Drugs Limited

https://www.betadrugslimited.com

Beta Drugs Limited specializes in the development, manufacture, and marketing of oncology formulations. The company provides a comprehensive portfolio of anti-cancer drugs across various therapeutic segments, including cytotoxic injectables, lyophilized products, tablets, and capsules. Its manufacturing capabilities encompass a wide range of oncology treatments such as chemotherapy agents and supportive care medications. The organization operates advanced production facilities designed to meet international quality standards, focusing on high-potency active pharmaceutical ingredients and finished dosage forms. The company serves diverse markets through its own branded products and contract manufacturing services, aiming to provide affordable and high-quality cancer care solutions. Its core competency lies in its specialized focus on the oncology niche and its integrated approach to pharmaceutical production.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 95% confidence The document is extremely short (186 characters) and contains only a digital signature with no substantive content or financial data. There is no indication of a report, announcement, or detailed information. It does not meet criteria for any specific report type and fits best as a Regulatory Filing (RNS) due to its minimal content and nature as a certification or attestation.
2024-09-30 English
Shareholders meeting
AGM Information Classification · 95% confidence The document is a detailed summary of the proceedings of the 19th Annual General Meeting (AGM) of Beta Drugs Limited held on 30th September 2024. It includes information about the meeting agenda, voting procedures, resolutions passed, and the declaration of results. The content focuses on the conduct and summary of the AGM rather than the full annual report or financial statements themselves. There is no indication that this document contains the full financial statements or detailed financial performance data, but rather it summarizes the meeting where such reports were discussed. Therefore, this document fits the category of AGM Information (AGM-R). The document length (13,362 characters) and detailed meeting content support this classification with high confidence.
2024-09-30 English
Copy of Newspaper Publication
AGM Information Classification · 95% confidence The document is a newspaper advertisement notice for the 19th Annual General Meeting (AGM) of Beta Drugs Ltd, specifying the date, time, and venue of the AGM. It includes details about the publication of the AGM notice in newspapers and is addressed to the National Stock Exchange of India Limited. The content is focused on informing about the AGM meeting and the notice publication rather than the AGM materials or presentations themselves. The document length is about 15,000 characters, but the content is primarily an announcement of the AGM notice publication, not the AGM report or presentation. Therefore, it fits the category of AGM Information (AGM-R) as it relates to materials shared or announcements made for the AGM, specifically the notice advertisement.
2024-09-06 English
Shareholders meeting
AGM Information Classification · 95% confidence The document is titled '19th Annual Report' of Beta Drugs Limited and contains detailed notices to shareholders about the Annual General Meeting (AGM). It includes agenda items such as adoption of audited financial statements for the fiscal year ended March 31, 2024, appointment and reappointment of directors, appointment of statutory auditors, remuneration revisions for managing directors and whole-time directors, and other corporate governance matters. The content is typical of AGM notices and materials that accompany the annual report but primarily focuses on the meeting agenda and resolutions to be passed at the AGM rather than the full annual report itself. The document length is 15,000 characters, which is substantial but the content is structured as a notice and resolutions for the AGM rather than a comprehensive annual report with full financial statements and management discussion and analysis. Therefore, this document fits best under AGM Information (AGM-R) as it is the notice and agenda for the Annual General Meeting, including shareholder resolutions and related information.
2024-09-05 English
Shareholders meeting
Regulatory Filings Classification · 95% confidence The document text is extremely short (186 characters) and contains no substantive content other than a digital signature and omitted images. There is no financial data, report content, or detailed information. It appears to be a certification or attestation document without any report or announcement details. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2024-08-31 English
Book Closure
Regulatory Filings Classification · 100% confidence The document text is extremely short (134 characters) and contains only a digital signature with no substantive content, financial data, or report information. It does not contain any report, announcement, or detailed information. Given the lack of content, this is best classified as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2024-08-31 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.